• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of slow release reagent of NFkB decoy oligodeoxynucleotides for the treatment of rheumatic arthritis

Research Project

Project/Area Number 13558109
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section展開研究
Research Field Biomedical engineering/Biological material science
Research InstitutionOSAKA UNIVERSITY

Principal Investigator

KANEDA Yasufumi  Osaka University, Graduate School of Medicine, Professor, 医学系研究科, 教授 (10177537)

Co-Investigator(Kenkyū-buntansha) SANO Akihiko  Sumitomo Pharmaceuticals Co. Ltd., Formulation Research Laboratories, 製剤技術研究所・創剤研究グループ, 主任研究員
MIRISHITA Ryuichi  Osaka University, Graduate School of Medicine, Professor, 医学系研究科, 教授 (40291439)
冨田 哲也  大阪大学, 医学系研究科, 助手 (30283766)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥12,700,000 (Direct Cost: ¥12,700,000)
Fiscal Year 2002: ¥5,400,000 (Direct Cost: ¥5,400,000)
Fiscal Year 2001: ¥7,300,000 (Direct Cost: ¥7,300,000)
Keywordsdecoy oligodeoxynucleotides / NFκB / drug delivery / polymer / molecular therapy / デコイオリゴヌクレオチド / 慢性関節リウマチ / 遺伝子治療 / HVJ-liposome / 遺伝子導入 / 徐放化製剤 / 転写因子
Research Abstract

We attempted to prolong release of NFkB oligodeoxynudeotid.es without degradation. First, we tested the efficiency of introduction of FITC-labeled oligonucleotides into cultured cells using atelocollagen. No fluorescence was detected at 48 hours after the transfer to HeLa, BHK-21 and human tongue cancer cell line SAS. Then, we developed HVJ (hemagglutinating virus of Japan ; Sendai virus) envelope vector which can introduce synthetic oligonucleotides, proteins, peptides and chemical drugs as well as genes. FITC-labeled oligonucleotides were incorporated into HVJ envelope vector by the treatment of mild detergent and centrifugation. Ten minutes after incubation of those cultured cells described above with the HVJ envelope vector, fluorescence was observed in almost all the nuclei of the cells. When NFkB decoy oligonucleotides were introduced into cancer cells such as SAS and HeLa cells using HVJ envelope vector, apoptosis after irradiation was enhanced by the suppression of NFkB-induced … More gene expression. When FITC-labeled NFkB decoy oligonucleotides were introduced into the joint space of Cynomolgus monkeys using HVJ envelope vector, fluorescence was detected at both synovium and articular cartilage. Next, HVJ envelope vector was embedded with various polymers. First, without polymer, HVJ envelope vector reaches spleen by intravenous injection and FITC-oligonucleotides were detected at the marginal zone of mouse spleen. Then, the vector containing luciferase gene was decorated with protamine suifate and the complex was injected into tail vein of mouse. Gene expression was detected exclusively in lung, not in spleen. Furthermore, when HVJ envelope vector mixed with heparin was injected into muscle or brain directly, gene expression was approximately 5 fold increased than that without heparin. The effect of polymers on slow release of the vector is being investigated, but we have got preliminary data suggesting that cationic polymers may enhance slow release of HVJ envelope vector. Less

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • Research Products

    (28 results)

All Other

All Publications (28 results)

  • [Publications] Yamamoto, S.: "A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma"Cancer Gene Therapy. (in press). (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Tomita, N.: "Targeted Gene Therapy for Rat Glomerulonephritis using HVJ-immunoliposomes"J.Gene Medicine. 4. 527-535 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kaneda, Y.: "HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system"Molecular Therapy. 6. 219-226 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Nakamura, H.: "Prevention and regeneration of atopic dermatitis by ointment containing NFkB decoy oligonucleotides in NC/Nga atopic mouse model"Gene Therapy. 9. 1221-1229 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Endoh, M.: "Fetal gene transfer by intra-uterine injection with microbubble-enhanced ultrasound"Molecular Therapy. 5. 501-505 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Taniyama Y.: "Local delivery of plasmid DNA into rat carotid artery using ultrasound"Circulation. 105. 1233-1239 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kaneda, Y.: "Pharmaceutical Gene Delivery Systems"Alain Rolland and Sean Sullivan(in press). (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Taniyama, Y., Tachibana, K., Hiraoka, K., Nainba, T., Yamasaki, K., Hashiya, N., Aoki, M., Ogihara, T., Kaneda, Y., and Morishita, R.: "Local delivery of plasmid DNA into rat carotid artery using ultrasound"Circulation. 105. 1233-1239 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Endoh, M., Koibuchi, N., Sato, M., Morishita, R., Kanzaki, T., Murata, Y. and Kaneda, Y: "Fetal gene transfer by intra-uterine injection with microbubble-enhanced ultrasound"Molecular Therapy. 5. 501-505 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Tomita, N., Morishita, R, Yamamoto, K., Higaki, J., Dzau, V. J., Ogihara, T., and Kaneda, Y: "Targeted Gene Therapy for Rat Glomerulonephritis using HVJ-intmtsnoliposomes"J. Gene Medicine. 4. 527-535 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Nakamura, T., Morishita, R., Asai, T., Tsuboniwa, N., Aoki, M., Sakonju, H., Yainasaki, K., Hashiya, N., Kaneda, Y., and Ogihara, T: "Molecular strategy using cis-element decoy of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model."Gene Therapy. 9. 488-494 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Tanjyama, Y, Tachibana, K., Hiraoka, K., Aoki, M., Yamamoto, S., Matsumoto, K., Nakamura, T., Ogihara, T., Kaneda,Y, and Morishita,: "Development of safe and efficient novel nonviral gene transfer using ultrasound ; enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle"Gene Therapy. 9. 372-380 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Nakamura, H., Morishita, R., and Kaneda, Y: "Molecular therapy via transcriptional regulation with double-stranded oligodeoxynucleotides as decoys"In Vivo. 16. 45-48 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kaneda, Y., Nakajima, T., Nishikawa, T., Yamamoto, S., Ikegami, H., Suzuki, N., Nakamura, H., Morishita, R, and Kotani, H: "HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system"Molecular Therapy. 6. 219-226 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Yamamoto, S.: "A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma"Cancer Gene Therapy. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Tomita, N.: "Targeted Gene Therapy for Rat Glomerulonephritis using HVJ-immunoliposomes"J. Gene Medicine. 4. 527-535 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kaneda, Y.: "HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system"Molecular Therapy. 6. 219-226 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakamura, H.: "Prevention and regeneration of atopic dermatitis by ointment containing NFkB decoy oligonucleotides in NC/Nga atopic mouse model"Gene Therapy. 9. 1221-1229 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Endoh, M.: "Fetal gene transfer by intra-uterine injection with microbubble-enhanced ultrasound"Molecular Therapy. 5. 501-505 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Taniyama Y.: "Local delivery of plasmid DNA into rat carotid artery using ultrasound"Circulation. 105. 1233-1239 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kaneda, Y.: "Pharmaceutical Gene Delivery Systems"Alain Rolland and Sean Sullivan (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Tsuboniwa, N., et al., Kaneda, Y.: "Safety evaluation of HVJ-AVE liposomes in nonhuman primates"Hum. Gene Therapy. 12. 469-487 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Nakamura, N., et al., Kaneda, Y.: "Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated With effective antisense gene inhibition"J. Biochem.. 129. 755-759 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kawamura, I., et al., Kaneda, Y.: "Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice"Gene therapy. 8. 905-912 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Ueno, T., et al., Kaneda, Y., Matsuda, H.: "Nuclear factor-kB decoy attenuates neuronal damage after global brain ischemia ; a future strategy for brain protection during circulatory arrest"Cardiopulomonary Support and Physiology. 122. 720-727 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Yokoseki, O., et al., Kaneda, Y., Isobe, M.: "cis Element decoy against nuclear factor-kB attenuates development of experimental autoimmune myocarditis in rats"Circulation Research. 89. 899-906 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Yoshimura, S., et al., Kaneda, Y., Ogihara, T.: "Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element decoy of nuclear factor-kB binding site as a novel molecular strategy"Gene Therapy. 8. 1635-1642 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kaneda, Y.: "Frontiers in Human Genetics"World Scientific. 396 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi